Cargando…

In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis

BACKGROUND: The APOE4 allele variant is the strongest known genetic risk factor for developing late-onset Alzheimer’s disease. The link between apolipoprotein E (apoE) and Alzheimer’s disease is likely due in large part to the impact of apoE on the metabolism of amyloid β (Aβ) within the brain. Mani...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulrich, Jason D, Burchett, Jack M, Restivo, Jessica L, Schuler, Dorothy R, Verghese, Philip B, Mahan, Thomas E, Landreth, Gary E, Castellano, Joseph M, Jiang, Hong, Cirrito, John R, Holtzman, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640999/
https://www.ncbi.nlm.nih.gov/pubmed/23601557
http://dx.doi.org/10.1186/1750-1326-8-13
_version_ 1782267960247713792
author Ulrich, Jason D
Burchett, Jack M
Restivo, Jessica L
Schuler, Dorothy R
Verghese, Philip B
Mahan, Thomas E
Landreth, Gary E
Castellano, Joseph M
Jiang, Hong
Cirrito, John R
Holtzman, David M
author_facet Ulrich, Jason D
Burchett, Jack M
Restivo, Jessica L
Schuler, Dorothy R
Verghese, Philip B
Mahan, Thomas E
Landreth, Gary E
Castellano, Joseph M
Jiang, Hong
Cirrito, John R
Holtzman, David M
author_sort Ulrich, Jason D
collection PubMed
description BACKGROUND: The APOE4 allele variant is the strongest known genetic risk factor for developing late-onset Alzheimer’s disease. The link between apolipoprotein E (apoE) and Alzheimer’s disease is likely due in large part to the impact of apoE on the metabolism of amyloid β (Aβ) within the brain. Manipulation of apoE levels and lipidation within the brain has been proposed as a therapeutic target for the treatment of Alzheimer’s disease. However, we know little about the dynamic regulation of apoE levels and lipidation within the central nervous system. We have developed an assay to measure apoE levels in the brain interstitial fluid of awake and freely moving mice using large molecular weight cut-off microdialysis probes. RESULTS: We were able to recover apoE using microdialysis from human cerebrospinal fluid (CSF) in vitro and mouse brain parenchyma in vivo. Microdialysis probes were inserted into the hippocampus of wild-type mice and interstitial fluid was collected for 36 hours. Levels of apoE within the microdialysis samples were determined by ELISA. The levels of apoE were found to be relatively stable over 36 hours. No apoE was detected in microdialysis samples from apoE KO mice. Administration of the RXR agonist bexarotene increased ISF apoE levels while ISF Aβ levels were decreased. Extrapolation to zero-flow analysis allowed us to determine the absolute recoverable concentration of apoE3 in the brain ISF of apoE3 KI mice. Furthermore, analysis of microdialysis samples by non-denaturing gel electrophoresis determined lipidated apoE particles in microdialysis samples were consistent in size with apoE particles from CSF. Finally, we found that the concentration of apoE in the brain ISF was dependent upon apoE isoform in human apoE KI mice, following the pattern apoE2>apoE3>apoE4. CONCLUSIONS: We are able to collect lipidated apoE from the brain of awake and freely moving mice and monitor apoE levels over the course of several hours from a single mouse. Our technique enables assessment of brain apoE dynamics under physiological and pathophysiological conditions and in response to therapeutic interventions designed to affect apoE levels and lipidation within the brain.
format Online
Article
Text
id pubmed-3640999
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36409992013-05-02 In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis Ulrich, Jason D Burchett, Jack M Restivo, Jessica L Schuler, Dorothy R Verghese, Philip B Mahan, Thomas E Landreth, Gary E Castellano, Joseph M Jiang, Hong Cirrito, John R Holtzman, David M Mol Neurodegener Methodology BACKGROUND: The APOE4 allele variant is the strongest known genetic risk factor for developing late-onset Alzheimer’s disease. The link between apolipoprotein E (apoE) and Alzheimer’s disease is likely due in large part to the impact of apoE on the metabolism of amyloid β (Aβ) within the brain. Manipulation of apoE levels and lipidation within the brain has been proposed as a therapeutic target for the treatment of Alzheimer’s disease. However, we know little about the dynamic regulation of apoE levels and lipidation within the central nervous system. We have developed an assay to measure apoE levels in the brain interstitial fluid of awake and freely moving mice using large molecular weight cut-off microdialysis probes. RESULTS: We were able to recover apoE using microdialysis from human cerebrospinal fluid (CSF) in vitro and mouse brain parenchyma in vivo. Microdialysis probes were inserted into the hippocampus of wild-type mice and interstitial fluid was collected for 36 hours. Levels of apoE within the microdialysis samples were determined by ELISA. The levels of apoE were found to be relatively stable over 36 hours. No apoE was detected in microdialysis samples from apoE KO mice. Administration of the RXR agonist bexarotene increased ISF apoE levels while ISF Aβ levels were decreased. Extrapolation to zero-flow analysis allowed us to determine the absolute recoverable concentration of apoE3 in the brain ISF of apoE3 KI mice. Furthermore, analysis of microdialysis samples by non-denaturing gel electrophoresis determined lipidated apoE particles in microdialysis samples were consistent in size with apoE particles from CSF. Finally, we found that the concentration of apoE in the brain ISF was dependent upon apoE isoform in human apoE KI mice, following the pattern apoE2>apoE3>apoE4. CONCLUSIONS: We are able to collect lipidated apoE from the brain of awake and freely moving mice and monitor apoE levels over the course of several hours from a single mouse. Our technique enables assessment of brain apoE dynamics under physiological and pathophysiological conditions and in response to therapeutic interventions designed to affect apoE levels and lipidation within the brain. BioMed Central 2013-04-19 /pmc/articles/PMC3640999/ /pubmed/23601557 http://dx.doi.org/10.1186/1750-1326-8-13 Text en Copyright © 2013 Ulrich et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methodology
Ulrich, Jason D
Burchett, Jack M
Restivo, Jessica L
Schuler, Dorothy R
Verghese, Philip B
Mahan, Thomas E
Landreth, Gary E
Castellano, Joseph M
Jiang, Hong
Cirrito, John R
Holtzman, David M
In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis
title In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis
title_full In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis
title_fullStr In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis
title_full_unstemmed In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis
title_short In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis
title_sort in vivo measurement of apolipoprotein e from the brain interstitial fluid using microdialysis
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640999/
https://www.ncbi.nlm.nih.gov/pubmed/23601557
http://dx.doi.org/10.1186/1750-1326-8-13
work_keys_str_mv AT ulrichjasond invivomeasurementofapolipoproteinefromthebraininterstitialfluidusingmicrodialysis
AT burchettjackm invivomeasurementofapolipoproteinefromthebraininterstitialfluidusingmicrodialysis
AT restivojessical invivomeasurementofapolipoproteinefromthebraininterstitialfluidusingmicrodialysis
AT schulerdorothyr invivomeasurementofapolipoproteinefromthebraininterstitialfluidusingmicrodialysis
AT verghesephilipb invivomeasurementofapolipoproteinefromthebraininterstitialfluidusingmicrodialysis
AT mahanthomase invivomeasurementofapolipoproteinefromthebraininterstitialfluidusingmicrodialysis
AT landrethgarye invivomeasurementofapolipoproteinefromthebraininterstitialfluidusingmicrodialysis
AT castellanojosephm invivomeasurementofapolipoproteinefromthebraininterstitialfluidusingmicrodialysis
AT jianghong invivomeasurementofapolipoproteinefromthebraininterstitialfluidusingmicrodialysis
AT cirritojohnr invivomeasurementofapolipoproteinefromthebraininterstitialfluidusingmicrodialysis
AT holtzmandavidm invivomeasurementofapolipoproteinefromthebraininterstitialfluidusingmicrodialysis